.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,736,124

« Back to Dashboard

Details for Patent: 5,736,124

Title: Aerosol formulations containing P134a and particulate medicament
Abstract:This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.
Inventor(s): Akehurst; Rachel Ann (Ware, GB3), Taylor; Anthony James (Ware, GB3), Wyatt; David Andrew (Ware, GB3)
Assignee: Glaxo Group Limited (London, GB2)
Filing Date:May 30, 1995
Application Number:08/453,820
Claims:1. A pharmaceutical aerosol formulation consisting essentially of (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane as propellant, and (iii) 0.01 to 5% w/w based upon the propellent of a polar cosolvent which is a C.sub.2-5 aliphatic alcohol or polyol or a mixture thereof, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.

2. A formulation as claimed in claim 1, wherein the polar cosolvent is present in an amount from 0.05 to 3% w/w based upon the propellant.

3. A formulation as claimed in claim 2, wherein said medicament is an anti-allergic, a bronchodilator or an anti-inflammatory steroid.

4. A formulation as claimed in claim 2 wherein said medicament is selected from the group consisting of salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof.

5. A formulation as claimed in claim 2 wherein said medicament is beclomethasone dipropionate or a physiologically acceptable solvate thereof.

6. A formulation as claimed in claim 2 wherein said medicament is selected from the group consisting of ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol rimiterol, terbutaline, isoetharine, tolubuterol, orciprenaline, (-)-4-amino-3,5-dichloro-.alpha.-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]-amino] methyl]benzene-methanol and physiologically acceptable salts thereof.

7. A formulation as claimed in claim 2 which contains two or more particulate medicaments.

8. A formulation as claimed in claim 2 which contains a particulate bronchodilatory medicament and a particulate anti-inflammatory medicament.

9. A formulation as claimed in claim 2 which contains salmeterol xinafoate in combination with fluticasone propionate.

10. A formulation as claimed in claim 2 which is free of surfactant.

11. A formulation as claimed in claim 2 wherein the polar cosolvent is ethanol.

12. A formulation as claimed in claim 2 wherein the medicament is present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation.

13. A formulation as claimed in claim 2 which has a respirable fraction of 20% or more by weight of the medicament.

14. A pharmaceutical aerosol formulation consisting of (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent which is C.sub.2-5 aliphatic alcohol or polyol or a mixture thereof, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

15. A formulation as claimed in claim 14 wherein the polar cosolvent is present in an amount from 0.05 to 3% w/w based upon the propellant.

16. A formulation as claimed in claim 15 wherein said medicament is selected from the group consisting of salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solyates thereof.

17. A formulation as claimed in claim 15 wherein said medicament is beclomethasone dipropionate or a physiologically acceptable solvate thereof.

18. A formulation as claimed in claim 15 wherein said medicament is selected from the group consisting of ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, orciprenaline, (-)-4-amino-3,5-dichloro-.alpha.-[[[6-[2-2(pyridinyl)ethoxy]hexyl]-amino]m ethyl]benzene-methanol and physiologically acceptable salts thereof.

19. A formulation as claimed in claim 15 which contains two or more particulate medicaments.

20. A formulation as claimed in claim 15 which contains a particulate bronchodilatory medicament and a particulate anti-inflammatory medicament.

21. A formulation as claimed in claim 15 which contains salmeterol xinafoate in combination with fluticasone propionate.

22. A formulation as claimed in claim 15 wherein said medicament is an anti-allergic, a bronchodilator or an anti-inflammatory steroid.

23. A formulation as claimed in claim 15 wherein the polar cosolvent is ethanol.

24. A formulation as claimed in claim 15 wherein the medicament is present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation.

25. A formulation as claimed in claim 15 which has a respirable fraction of 20% or more by weight of the medicament.

26. A formulation as claimed in claim 2 wherein the polar cosolvent is ethanol.

27. A formulation as claimed in claim 22 wherein the polar cosolvent is ethanol.

28. A pharmaceutical aerosol formulation consisting essentially of (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane as propellant and (iii) 0.05 to 5% w/w based upon the propellant of a polar cosolvent being ethanol, isopropanol, propylene glycol or a mixture thereof, the particulate medicament being present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.

29. A formulation as claimed in claim 28 which is free of surfactant.

30. A formulation as claimed in claim 28 which contains 0.05 to 3% w/w based upon the propellant of a polar cosolvent.

31. A formulation as claimed in claim 29 which contains 0.05 to 3% w/w based upon the propellant of a polar cosolvent.

32. A formulation as claimed in claim 28 wherein the polar cosolvent is ethanol.

33. A formulation as claimed in claim 29 wherein the polar cosolvent is ethanol.

34. A formulation as claimed in claim 28 wherein said medicament is formoterol.

35. A formulation as claimed in claim 29 wherein said medicament is formoterol.

36. A pharmaceutical aerosol formulation consisting of (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane as propellant and (iii) 0.05 to 5% w/w based upon the propellant of a polar cosolvent being ethanol, isopropanol, propylene glycol or a mixture thereof, the particulate medicament being present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

37. A formulation as claimed in claim 36 which contains 0.05 to 3% w/w based upon the propellant of a polar cosolvent.

38. A formulation as claimed in claim 36 wherein the polar cosolvent is ethanol.

39. A formulation as claimed in claim 1 wherein the polar cosolvent is present in an amount of 0.05 to 5% w/w based upon the propellant.

40. A pharmaceutical aerosol formulation consisting of (i) a particulate medicament which is salmeterol or physiologically acceptable salts thereof, (ii) 1,1,1,2-tetrafluoroethane as propellant and (iii) 0.05 to 5% w/w based upon the propellant of a polar cosolvent being ethanol, isopropanol, propylene glycol or a mixture thereof, the particulate medicament being present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

41. A formulation as claimed in claim 40 wherein the polar cosolvent is ethanol.

42. A formulation as claimed in claim 40 wherein the salmeterol is in the form of salmeterol xinafoate.

43. A formulation as claimed in claim 42 wherein the polar cosolvent is ethanol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc